Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1
A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.
